We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF

100 hedge funds and large institutions have $92.8M invested in Invesco Biotechnology & Genome ETF in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $78.5M → $92.8M (+$14.3M)

17% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 24

4.14% more ownership

Funds ownership: 31.93%36.06% (+4.1%)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

2% less funds holding

Funds holding: 102100 (-2)

Holders
100
Holders Change
-2
Holders Change %
-1.96%
% of All Funds
1.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
28
Reduced
24
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HNB
101
Huntington National Bank
Ohio
$65
Two Sigma Investments
102
Two Sigma Investments
New York
-$324K -5,000 Closed
Citadel Advisors
103
Citadel Advisors
Florida
-$266K -4,111 Closed
BRWA
104
B. Riley Wealth Advisors
Florida
-$205K -3,588 Closed
SA
105
Strategic Advisors
New York
-$227K -3,501 Closed
PAG
106
Private Advisor Group
New Jersey
-$224K -3,465 Closed
Susquehanna International Group
107
Susquehanna International Group
Pennsylvania
-$217K -3,348 Closed
ATC
108
Adirondack Trust Company
New York
-$3.04K -47 Closed

PBE Hedge Fund Activity: Q2 2024 in Review

100 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2024, worth a combined $92.8M — up 18% from $78.5M a quarter earlier.

Fund positioning in PBE was balanced in Q2 2024: 7 funds opened new positions, 7 closed out, 28 added to existing stakes and 24 trimmed.

The largest buyer was Gerber Kawasaki Wealth & Investment Management, adding an estimated $16.4M. The largest seller was Equitable Holdings, cutting an estimated $2.06M.

  • 100 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2024, down from 102 in Q1 2024.
  • Funds reported $92.8M of Invesco Biotechnology & Genome ETF stock for Q2 2024, up 18% quarter-over-quarter.
  • 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2024 and 7 closed out, a net change of 0 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q2 2024 was Gerber Kawasaki Wealth & Investment Management, an estimated $16.4M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q2 2024 was Equitable Holdings, an estimated $2.06M sold.

Based on aggregated 13F filings for Q2 2024.